GENESIS Ventures

Our vehicle and our investiment policy

GENESIS Biomed is proud to announce the creation of GENESIS Ventures, an investment vehicle located in Barcelona and built up in partnership with family offices. The new fund is sized in 1.220.000 € and will invest in recently created Start-ups or entrepreneurial projects with a clear aim to develop innovative products through the creation of a Start-up company in the biomedical and biotechnological field (therapeutics, diagnostics, medical devices and others). The investment platform is envisaged as a very early-stage tool to help the development of excellent scientific projects to reach key value milestones to attract a first round of investment from venture or corporate funds.

GENESIS Ventures will fund projects or start-ups with 50.000 to 100.000 € tickets depending on the identified development needs. The investment period of the vehicle will finish in October 2019.

GENESIS Biomed will be the company in charge of the management of the fund. For more information please email to contact@genesis-biomed.com

Phase 1: Pre-foundation of the spin-off

Our Total Fund: 1,2 M€

Tickets*: 50.000 – 100.000 €

Investment Agreement is signed with Research Center and Research Group

Max. investment period*: 1 year

GENESIS Biomed will manage the projects and will inform the Investments Committee

Phase 2: Foundation of the spin-off

After the investment period, the spinoff company should be founded. If the spinoff is not founded and the project is licensed to a third party, the Investment Agreement regulates the return to GENESIS Ventures (via upfront royalties).

In the foundation, GENESIS Ventures acquires the corresponding shares committed in the Investment Agreement. Our policy is not to become a major shareholder.

After the foundation, GENESIS Biomed will help the new spinoff (becoming potential GENESIS’ client) in the fundraising process in order to close a series A with Venture Capital investors.

Exit scenario: the standard exit scenario for Venture Capital once the Company is acquired or the project is out-licensed to a third party.

*Orientative figures. These will be fixed in a case-by-case basis